RANKL/RANK-beyond bones

Journal of Molecular Medicine

Volumn 89, Issue 7, 2011, Pages 647-656

  Hanada, Reiko ^a   Hanada, Toshikatsu ^a   Sigl, Verena ^a   Schramek, Daniel ^a   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Cancer; Central nervous systems; Fever; Immunology; Osteoclastogenesis; RANKL RANK system

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CD40 LIGAND; COLECALCIFEROL; ESTRADIOL; GESTAGEN; GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PROLACTIN; PROSTAGLANDIN E2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BONE METASTASIS; BONE REMODELING; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER INHIBITION; FEVER; HUMAN; IMMUNE SYSTEM; MAMMARY GLAND; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THERMOREGULATION;

ANIMALS; BONE AND BONES; HUMANS; IMMUNE SYSTEM; LACTATION; NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 79959936606     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0749-z     Document Type: Review

References (85)

1. DL Lacey E Timms HL Tan MJ Kelley CR Dunstan T Burgess R Elliott A Colombero G Elliott S Scully H Hsu J Sullivan N Hawkins E Davy C Capparelli A Eli YX Qian S Kaufman I Sarosi V Shalhoub G Senaldi J Guo J Delaney WJ Boyle 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 9568710 10.1016/S0092-8674(00) 81569-X 1:CAS:528:DyaK1cXivVyhtrg%3D (Pubitemid 28180851)
2. DM Anderson E Maraskovsky WL Billingsley WC Dougall ME Tometsko ER Roux MC Teepe RF DuBose D Cosman L Galibert 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 175 179 10.1038/36593 9367155 10.1038/36593 1:CAS:528:DyaK2sXnsVOgurY%3D (Pubitemid 27507987)
3. BR Wong J Rho J Arron E Robinson J Orlinick M Chao S Kalachikov E Cayani FS Bartlett 3rd WN Frankel SY Lee Y Choi 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells J Biol Chem 272 25190 25194 9312132 10.1074/jbc.272.40.25190 1:CAS:528:DyaK2sXms1ehsbo%3D (Pubitemid 27415705)
4. H Yasuda N Shima N Nakagawa K Yamaguchi M Kinosaki S Mochizuki A Tomoyasu K Yano M Goto A Murakami E Tsuda T Morinaga K Higashio N Udagawa N Takahashi T Suda 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 3597 3602 9520411 10.1073/pnas.95.7.3597 1:CAS:528: DyaK1cXitlKjsLY%3D (Pubitemid 28173173)
5. H Yasuda N Shima N Nakagawa SI Mochizuki K Yano N Fujise Y Sato M Goto K Yamaguchi M Kuriyama T Kanno A Murakami E Tsuda T Morinaga K Higashio 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1329 1337 9492069 10.1210/en.139.3.1329 (Pubitemid 28510154)
6. E Tsuda M Goto S Mochizuki K Yano F Kobayashi T Morinaga K Higashio 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis Biochem Biophys Res Commun 234 137 142 9168977 10.1006/bbrc.1997.6603 1:CAS:528:DyaK2sXjt1ynsLw%3D (Pubitemid 27267548)
7. WS Simonet DL Lacey CR Dunstan M Kelley MS Chang R Luthy HQ Nguyen S Wooden L Bennett T Boone G Shimamoto M DeRose R Elliott A Colombero HL Tan G Trail J Sullivan E Davy N Bucay L Renshaw-Gegg TM Hughes D Hill W Pattison P Campbell S Sander G Van J Tarpley P Derby R Lee WJ Boyle 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319 9108485 10.1016/S0092-8674(00)80209-3 1:CAS:528:DyaK2sXislCgtLc%3D (Pubitemid 27199902)
8. N Nakagawa M Kinosaki K Yamaguchi N Shima H Yasuda K Yano T Morinaga K Higashio 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis Biochem Biophys Res Commun 253 395 400 10.1006/bbrc.1998.9788 9878548 10.1006/bbrc.1998.9788 1:CAS:528: DyaK1MXhs12ntw%3D%3D (Pubitemid 29026714)
9. H Hsu DL Lacey CR Dunstan I Solovyev A Colombero E Timms HL Tan G Elliott MJ Kelley I Sarosi L Wang XZ Xia R Elliott L Chiu T Black S Scully C Capparelli S Morony G Shimamoto MB Bass WJ Boyle 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci USA 96 3540 3545 10097072 10.1073/pnas.96.7.3540 1:CAS:528:DyaK1MXjslCitL8%3D (Pubitemid 29168945)
10. YY Kong H Yoshida I Sarosi HL Tan E Timms C Capparelli S Morony AJ Oliveira-dos-Santos G Van A Itie W Khoo A Wakeham CR Dunstan DL Lacey TW Mak WJ Boyle JM Penninger 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 315 323 10.1038/16852 9950424 10.1038/16852 1:CAS:528:DyaK1MXhtVOqs7w%3D (Pubitemid 29061638)
11. WC Dougall M Glaccum K Charrier K Rohrbach K Brasel T De Smedt E Daro J Smith ME Tometsko CR Maliszewski A Armstrong V Shen S Bain D Cosman D Anderson PJ Morrissey JJ Peschon J Schuh 1999 RANK is essential for osteoclast and lymph node development Genes Dev 13 2412 2424 10500098 10.1101/gad.13.18.2412 1:CAS:528:DyaK1MXmsVCgtr4%3D (Pubitemid 29453612)
12. J Li I Sarosi XQ Yan S Morony C Capparelli HL Tan S McCabe R Elliott S Scully G Van S Kaufman SC Juan Y Sun J Tarpley L Martin K Christensen J McCabe P Kostenuik H Hsu F Fletcher CR Dunstan DL Lacey WJ Boyle 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proc Natl Acad Sci USA 97 1566 1571 10677500 10.1073/pnas.97.4.1566 1:CAS:528:DC%2BD3cXhsFCrsL4%3D (Pubitemid 30118482)
13. SW Rossi MY Kim A Leibbrandt SM Parnell WE Jenkinson SH Glanville FM McConnell HS Scott JM Penninger EJ Jenkinson PJ Lane G Anderson 2007 RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla J Exp Med 204 1267 1272 10.1084/jem.20062497 17502664 10.1084/jem.20062497 1:CAS:528: DC%2BD2sXms1aktrg%3D (Pubitemid 46919863)
14. K Loser A Mehling S Loeser J Apelt A Kuhn S Grabbe T Schwarz JM Penninger S Beissert 2006 Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells Nat Med 12 1372 1379 10.1038/nm1518 17143276 10.1038/nm1518 1:CAS:528:DC%2BD28Xht1OntbnF (Pubitemid 44924495)
15. YY Kong U Feige I Sarosi B Bolon A Tafuri S Morony C Capparelli J Li R Elliott S McCabe T Wong G Campagnuolo E Moran ER Bogoch G Van LT Nguyen PS Ohashi DL Lacey E Fish WJ Boyle JM Penninger 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 304 309 10.1038/46303 10580503 10.1038/46303 1:CAS:528:DyaK1MXnvFShsLg%3D (Pubitemid 129516268)
16. JE Fata YY Kong J Li T Sasaki J Irie-Sasaki RA Moorehead R Elliott S Scully EB Voura DL Lacey WJ Boyle R Khokha JM Penninger 2000 The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development Cell 103 41 50 11051546 10.1016/S0092-8674(00)00103-3 1:CAS:528:DC%2BD3cXnt1yqtbw%3D
17. DH Jones T Nakashima OH Sanchez I Kozieradzki SV Komarova I Sarosi S Morony E Rubin R Sarao CV Hojilla V Komnenovic YY Kong M Schreiber SJ Dixon SM Sims R Khokha T Wada JM Penninger 2006 Regulation of cancer cell migration and bone metastasis by RANKL Nature 440 692 696 10.1038/nature04524 16572175 10.1038/nature04524 1:CAS:528:DC%2BD28XivFWgtb8%3D
18. A Mizuno N Amizuka K Irie A Murakami N Fujise T Kanno Y Sato N Nakagawa H Yasuda S Mochizuki T Gomibuchi K Yano N Shima N Washida E Tsuda T Morinaga K Higashio H Ozawa 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin Biochem Biophys Res Commun 247 610 615 9647741 10.1006/bbrc.1998.8697 1:CAS:528:DyaK1cXkt12htr8%3D (Pubitemid 28418439)
19. N Bucay I Sarosi CR Dunstan S Morony J Tarpley C Capparelli S Scully HL Tan W Xu DL Lacey WJ Boyle WS Simonet 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1260 1268 9573043 10.1101/gad.12.9.1260 1:CAS:528:DyaK1cXjtVejsrs%3D (Pubitemid 28213402)
20. G Karsenty EF Wagner 2002 Reaching a genetic and molecular understanding of skeletal development Dev Cell 2 389 406 11970890 10.1016/S1534-5807(02)00157- 0 1:CAS:528:DC%2BD38Xjt1ersb4%3D (Pubitemid 34436569)
21. LE Theill WJ Boyle JM Penninger 2002 RANK-L and RANK: T cells, bone loss, and mammalian evolution Annu Rev Immunol 20 795 823 10.1146/annurev.immunol.20. 100301.064753 11861618 10.1146/annurev.immunol.20.100301.064753 1:CAS:528:DC%2BD38XjtlWgtbo%3D (Pubitemid 34293440)
22. WJ Boyle WS Simonet DL Lacey 2003 Osteoclast differentiation and activation Nature 423 337 342 10.1038/nature01658 12748652 10.1038/nature01658 1:CAS:528:DC%2BD3sXjs1ynu7g%3D (Pubitemid 40852708)
23. T Suda N Takahashi N Udagawa E Jimi MT Gillespie TJ Martin 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr Rev 20 345 357 10368775 10.1210/er.20.3.345 1:CAS:528:DyaK1MXktVaqtLg%3D (Pubitemid 30649812)
24. AE Hughes SH Ralston J Marken C Bell H MacPherson RG Wallace W van Hul MP Whyte K Nakatsuka L Hovy DM Anderson 2000 Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis Nat Genet 24 45 48 10.1038/71667 10615125 10.1038/71667 1:CAS:528:DC%2BD3cXks1emsQ%3D%3D (Pubitemid 30041418)
25. MP Whyte S Mumm 2004 Heritable disorders of the RANKL/OPG/RANK signaling pathway J Musculoskelet Neuronal Interact 4 254 267 15615493 1:CAS:528:DC%2BD2cXhtVGmtbrI (Pubitemid 39504353)
26. T Cundy M Hegde D Naot B Chong A King R Wallace J Mulley DR Love J Seidel M Fawkner T Banovic KE Callon AB Grey IR Reid CA Middleton-Hardie J Cornish 2002 A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype Hum Mol Genet 11 2119 2127 12189164 10.1093/hmg/11.18.2119 1:CAS:528:DC%2BD38Xms1Gnu7o%3D (Pubitemid 34994000)
27. B Chong M Hegde M Fawkner S Simonet H Cassinelli M Coker J Kanis J Seidel C Tau B Tuysuz B Yuksel D Love 2003 Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype J Bone Miner Res 18 2095 2104 10.1359/jbmr.2003.18.12.2095 14672344 10.1359/jbmr.2003.18.12.2095 1:CAS:528:DC%2BD3sXhtVSqtr7O (Pubitemid 37463303)
28. MP Whyte AE Hughes 2002 Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis J Bone Miner Res 17 26 29 10.1359/jbmr.2002.17.1. 26 11771666 10.1359/jbmr.2002.17.1.26 1:CAS:528:DC%2BD38XktFyisA%3D%3D (Pubitemid 33150993)
29. C Sobacchi A Frattini MM Guerrini M Abinun A Pangrazio L Susani R Bredius G Mancini A Cant N Bishop P Grabowski A Del Fattore C Messina G Errigo FP Coxon DI Scott A Teti MJ Rogers P Vezzoni A Villa MH Helfrich 2007 Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL Nat Genet 39 960 962 10.1038/ng2076 17632511 10.1038/ng2076 1:CAS:528:DC%2BD2sXot1CmsLg%3D (Pubitemid 47185178)
30. JC Crockett DJ Mellis DI Scott MH Helfrich 2011 New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis Osteoporos Int 22 1 20 10.1007/s00198-010-1272-8 20458572 10.1007/s00198-010-1272-8 1:CAS:528:DC%2BC3MXjtVaqsQ%3D%3D
31. MM Guerrini C Sobacchi B Cassani M Abinun SS Kilic A Pangrazio D Moratto E Mazzolari J Clayton-Smith P Orchard FP Coxon MH Helfrich JC Crockett D Mellis A Vellodi I Tezcan LD Notarangelo MJ Rogers P Vezzoni A Villa A Frattini 2008 Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations Am J Hum Genet 83 64 76 10.1016/j.ajhg.2008.06.015 18606301 10.1016/j.ajhg.2008.06.015 1:CAS:528:DC%2BD1cXos1Cisrs%3D (Pubitemid 351916706)
32. HG Bone MA Bolognese CK Yuen DL Kendler H Wang Y Liu J San Martin 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2149 2157 10.1210/jc.2007-2814 18381571 10.1210/jc.2007-2814 1:CAS:528:DC%2BD1cXntFamtrg%3D (Pubitemid 351831529)
33. A Lipton GG Steger J Figueroa C Alvarado P Solal-Celigny JJ Body R de Boer R Berardi P Gascon KS Tonkin R Coleman AH Paterson MC Peterson M Fan A Kinsey S Jun 2007 Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 4431 4437 10.1200/JCO.2007.11.8604 17785705 10.1200/JCO.2007.11. 8604 1:CAS:528:DC%2BD2sXht1ertrjP (Pubitemid 350013849)
34. MR McClung EM Lewiecki SB Cohen MA Bolognese GC Woodson AH Moffett M Peacock PD Miller SN Lederman CH Chesnut D Lain AJ Kivitz DL Holloway C Zhang MC Peterson PJ Bekker 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 831 10.1056/NEJMoa044459 16495394 10.1056/NEJMoa044459 1:CAS:528:DC%2BD28Xhsl2gs7o%3D (Pubitemid 43290920)
35. PD Miller MA Bolognese EM Lewiecki MR McClung B Ding M Austin Y Liu J San Martin 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222 229 10.1016/j.bone.2008.04.007 18539106 10.1016/j.bone.2008.04.007 1:CAS:528:DC%2BD1cXosVOitrk%3D
36. JP Brown RL Prince C Deal RR Recker DP Kiel LH de Gregorio P Hadji LC Hofbauer JM Alvaro-Gracia H Wang M Austin RB Wagman R Newmark C Libanati J San Martin HG Bone 2009 Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 14 1 34 10.1359/jbmr.080910
37. GK Ellis HG Bone R Chlebowski D Paul S Spadafora J Smith M Fan S Jun 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 4875 4882 10.1200/JCO.2008.16.3832 18725648 10.1200/JCO.2008.16.3832 1:CAS:528: DC%2BD1cXhtlGitrzO
38. SR Cummings J San Martin MR McClung ES Siris R Eastell IR Reid P Delmas HB Zoog M Austin A Wang S Kutilek S Adami J Zanchetta C Libanati S Siddhanti C Christiansen 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 10.1056/NEJMoa0809493 19671655 10.1056/NEJMoa0809493 1:CAS:528:DC%2BD1MXhtVWls7nF
39. MR Smith B Egerdie N Hernandez Toriz R Feldman TL Tammela F Saad J Heracek M Szwedowski C Ke A Kupic BZ Leder C Goessl 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 745 755 10.1056/NEJMoa0809003 19671656 10.1056/NEJMoa0809003 1:CAS:528: DC%2BD1MXhtVWls7rF
40. E Maldonado-Gonzales P Pietschmann 2010 An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases Wien Med Wochenschr 160 458 463 10.1007/s10354-010-0812-3 20714812 10.1007/s10354-010- 0812-3
41. EM Lewiecki PD Miller MR McClung SB Cohen MA Bolognese Y Liu A Wang S Siddhanti LA Fitzpatrick 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 1832 1841 10.1359/jbmr.070809 17708711 10.1359/jbmr.070809 1:CAS:528:DC%2BD2sXhsVyjtrjF (Pubitemid 351229299)
42. JR Arron Y Choi 2000 Bone versus immune system Nature 408 535 536 10.1038/35046196 11117729 10.1038/35046196 1:CAS:528:DC%2BD3cXovFWku70%3D
43. H Takayanagi 2007 Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems Nat Rev Immunol 7 292 304 10.1038/nri2062 17380158 10.1038/nri2062 1:CAS:528:DC%2BD2sXjtlyhurc%3D (Pubitemid 46480961)
44. MC Walsh N Kim Y Kadono J Rho SY Lee J Lorenzo Y Choi 2006 Osteoimmunology: interplay between the immune system and bone metabolism Annu Rev Immunol 24 33 63 10.1146/annurev.immunol.24.021605.090646 16551243 10.1146/annurev.immunol.24.021605.090646 1:CAS:528:DC%2BD28XkvFSqt74%3D
45. D Kim RE Mebius JD MacMicking S Jung T Cupedo Y Castellanos J Rho BR Wong R Josien N Kim PD Rennert Y Choi 2000 Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE J Exp Med 192 1467 1478 11085748 10.1084/jem.192.10.1467 1:CAS:528:DC%2BD3cXotlaisrY%3D
46. TK Starr SC Jameson KA Hogquist 2003 Positive and negative selection of T cells Annu Rev Immunol 21 139 176 10.1146/annurev.immunol.21.120601.141107 12414722 10.1146/annurev.immunol.21.120601.141107 1:CAS:528:DC%2BD3sXjtF2isr4%3D (Pubitemid 37174529)
47. B Kyewski L Klein 2006 A central role for central tolerance Annu Rev Immunol 24 571 606 10.1146/annurev.immunol.23.021704.115601 16551260 10.1146/annurev.immunol.23.021704.115601 1:CAS:528:DC%2BD28XkvFSqtLk%3D
48. T Akiyama Y Shimo H Yanai J Qin D Ohshima Y Maruyama Y Asaumi J Kitazawa H Takayanagi JM Penninger M Matsumoto T Nitta Y Takahama J Inoue 2008 The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance Immunity 29 423 437 10.1016/j.immuni.2008.06.015 18799149 10.1016/j.immuni.2008.06.015 1:CAS:528:DC%2BD1cXhtF2jtLjK
49. Y Hikosaka T Nitta I Ohigashi K Yano N Ishimaru Y Hayashi M Matsumoto K Matsuo JM Penninger H Takayanagi Y Yokota H Yamada Y Yoshikai J Inoue T Akiyama Y Takahama 2008 The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator Immunity 29 438 450 10.1016/j.immuni.2008.06.018 18799150 10.1016/j.immuni.2008. 06.018 1:CAS:528:DC%2BD1cXhtF2jtLjL
50. GW Robinson AB Karpf K Kratochwil 1999 Regulation of mammary gland development by tissue interaction J Mammary Gland Biol Neoplasia 4 9 19 10219903 10.1023/A:1018748418447 1:STN:280:DyaK1M3jsFejuw%3D%3D
51. GW Robinson L Hennighausen PF Johnson 2000 Side-branching in the mammary gland: the progesterone-Wnt connection Genes Dev 14 889 894 10783160 1:CAS:528:DC%2BD3cXivFylsbk%3D (Pubitemid 30252997)
52. G Karsenty 1999 The genetic transformation of bone biology Genes Dev 13 3037 3051 10601030 10.1101/gad.13.23.3037 1:CAS:528:DC%2BD3cXhtFOitQ%3D%3D (Pubitemid 30016104)
53. GA Rodan TJ Martin 2000 Therapeutic approaches to bone diseases Science 289 1508 1514 10968781 10.1126/science.289.5484.1508 1:CAS:528: DC%2BD3cXmt1Kgsb4%3D
54. SL Teitelbaum FP Ross 2003 Genetic regulation of osteoclast development and function Nat Rev Genet 4 638 649 10.1038/nrg1122 12897775 10.1038/nrg1122 1:CAS:528:DC%2BD3sXlvFaqtrY%3D (Pubitemid 36917505)
55. S Srivastava M Matsuda Z Hou JP Bailey R Kitazawa MP Herbst ND Horseman 2003 Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells J Biol Chem 278 46171 46178 10.1074/jbc. M308545200M308545200 12952963 10.1074/jbc.M308545200 1:CAS:528: DC%2BD3sXosl2iu78%3D (Pubitemid 37432768)
56. Y Cao G Bonizzi TN Seagroves FR Greten R Johnson EV Schmidt M Karin 2001 IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development Cell 107 763 775 11747812 10.1016/S0092-8674(01)00599-2 1:CAS:528:DC%2BD38XhtFymtQ%3D%3D (Pubitemid 34033669)
57. NS Kim HJ Kim BK Koo MC Kwon YW Kim Y Cho Y Yokota JM Penninger YY Kong 2006 Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2 Mol Cell Biol 26 1002 1013 10.1128/MCB.26.3. 1002-1013.2006 16428453 10.1128/MCB.26.3.1002-1013.2006 1:CAS:528: DC%2BD28XhtVOnsrk%3D (Pubitemid 43146493)
58. H Kouros-Mehr JW Kim SK Bechis Z Werb 2008 GATA-3 and the regulation of the mammary luminal cell fate Curr Opin Cell Biol 20 164 170 10.1016/j.ceb.2008.02.003 18358709 10.1016/j.ceb.2008.02.003 1:CAS:528:DC%2BD1cXks1Gnurk%3D
59. JE Visvader GJ Lindeman 2003 Transcriptional regulators in mammary gland development and cancer Int J Biochem Cell Biol 35 1034 1051 12672473 10.1016/S1357-2725(03)00030-X 1:CAS:528:DC%2BD3sXisFWnurs%3D (Pubitemid 36369490)
60. GR Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 584 593 10.1038/nrc867 12154351 10.1038/nrc867 1:CAS:528:DC%2BD38XlslGqsLo%3D (Pubitemid 37328925)
61. IJ Fidler 2003 The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited Nat Rev Cancer 3 453 458 10.1038/nrc1098 12778135 10.1038/nrc1098 1:CAS:528:DC%2BD3sXktFOnsbg%3D (Pubitemid 37328849)
62. B Weigelt JL Peterse LJ van 't Veer 2005 Breast cancer metastasis: markers and models Nat Rev Cancer 5 591 602 10.1038/nrc1670 16056258 10.1038/nrc1670 1:CAS:528:DC%2BD2MXmvVCltrg%3D (Pubitemid 41081385)
63. WC Dougall M Chaisson 2006 The RANK/RANKL/OPG triad in cancer-induced bone diseases Cancer Metastasis Rev 25 541 549 10.1007/s10555-006-9021-3 17180711 10.1007/s10555-006-9021-3 1:CAS:528:DC%2BD2sXisVyruw%3D%3D (Pubitemid 46071863)
64. J Southby MW Kissin JA Danks JA Hayman JM Moseley MA Henderson RC Bennett TJ Martin 1990 Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer Cancer Res 50 7710 7716 2253214 1:STN:280:DyaK3M%2FntVGhtw%3D%3D
65. JL Luo W Tan JM Ricono O Korchynskyi M Zhang SL Gonias DA Cheresh M Karin 2007 Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin Nature 446 690 694 10.1038/nature05656 17377533 10.1038/nature05656 1:CAS:528:DC%2BD2sXjslOlsLk%3D (Pubitemid 46606879)
66. K Fizazi A Lipton X Mariette JJ Body Y Rahim JR Gralow G Gao L Wu W Sohn S Jun 2009 Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 1564 1571 10.1200/JCO.2008.19.2146 19237632 10.1200/JCO.2008.19.2146 1:CAS:528:DC%2BD1MXltVOhtr0%3D
67. AT Stopeck A Lipton JJ Body GG Steger K Tonkin RH de Boer M Lichinitser Y Fujiwara DA Yardley M Viniegra M Fan Q Jiang R Dansey S Jun A Braun 2010 Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 5132 5139 10.1200/JCO.2010.29.7101 21060033 10.1200/JCO.2010.29.7101 1:CAS:528:DC%2BC3MXhtlakt7o%3D
68. S Pece D Tosoni S Confalonieri G Mazzarol M Vecchi S Ronzoni L Bernard G Viale PG Pelicci PP Di Fiore 2010 Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content Cell 140 62 73 10.1016/j.cell.2009.12.007 20074520 10.1016/j.cell.2009.12.007 1:CAS:528:DC%2BC3cXkvVWiur0%3D
69. ML Asselin-Labat F Vaillant JM Sheridan B Pal D Wu ER Simpson H Yasuda GK Smyth TJ Martin GJ Lindeman JE Visvader 2010 Control of mammary stem cell function by steroid hormone signalling Nature 465 798 802 10.1038/nature09027 20383121 10.1038/nature09027 1:CAS:528:DC%2BC3cXksFakurg%3D
70. PA Joshi HW Jackson AG Beristain MA Di Grappa PA Mote CL Clarke J Stingl PD Waterhouse R Khokha 2010 Progesterone induces adult mammary stem cell expansion Nature 465 803 807 10.1038/nature09091 20445538 10.1038/nature09091 1:CAS:528:DC%2BC3cXls12ru7c%3D
71. MC Pike RK Peters W Cozen NM Probst-Hensch JC Felix PC Wan TM Mack 1997 Estrogen-progestin replacement therapy and endometrial cancer J Natl Cancer Inst 89 1110 1116 9262248 10.1093/jnci/89.15.1110 1:STN:280:DyaK2svgsVWlsA%3D%3D (Pubitemid 27337924)
72. D Schramek A Leibbrandt V Sigl L Kenner JA Pospisilik HJ Lee R Hanada PA Joshi A Aliprantis L Glimcher M Pasparakis R Khokha CJ Ormandy M Widschwendter G Schett JM Penninger 2010 Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer Nature 468 98 102 10.1038/nature09387 20881962 10.1038/nature09387 1:CAS:528:DC%2BC3cXht1ajtbvI
73. E Gonzalez-Suarez AP Jacob J Jones R Miller MP Roudier-Meyer R Erwert J Pinkas D Branstetter WC Dougall 2010 RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis Nature 468 103 107 10.1038/nature09495 20881963 10.1038/nature09495 1:CAS:528:DC%2BC3cXht1ajur7J
74. JD Hasday KD Fairchild C Shanholtz 2000 The role of fever in the infected host Microbes Infect 2 1891 1904 11165933 10.1016/S1286-4579(00)01337-X 1:STN:280:DC%2BD3MvitFOgtg%3D%3D (Pubitemid 32065688)
75. JK Elmquist TE Scammell CB Saper 1997 Mechanisms of CNS response to systemic immune challenge: the febrile response Trends Neurosci 20 565 570 9416669 10.1016/S0166-2236(97)01138-7 1:CAS:528:DyaK2sXnvFWnt7Y%3D (Pubitemid 27508968)
76. SF Morrison K Nakamura CJ Madden 2008 Central control of thermogenesis in mammals Exp Physiol 93 773 797 10.1113/expphysiol.2007.041848 18469069 10.1113/expphysiol.2007.041848 (Pubitemid 351904256)
77. GN Luheshi 1998 Cytokines and fever. Mechanisms and sites of action Ann NY Acad Sci 856 83 89 9917868 10.1111/j.1749-6632.1998.tb08316.x 1:CAS:528:DyaK1cXnsVClsro%3D (Pubitemid 28517340)
78. Bartfai T, Conti B. Fever. ScientificWorld Journal 10:490-503, doi: 10.1100/tsw.2010.50
79. V Kartsogiannis H Zhou NJ Horwood RJ Thomas DK Hards JM Quinn P Niforas KW Ng TJ Martin MT Gillespie 1999 Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues Bone 25 525 534 10574572 10.1016/S8756-3282(99)00214-8 1:CAS:528:DyaK1MXmvVKjurg%3D (Pubitemid 29469458)
80. R Hanada A Leibbrandt T Hanada S Kitaoka T Furuyashiki H Fujihara J Trichereau M Paolino F Qadri R Plehm S Klaere V Komnenovic H Mimata H Yoshimatsu N Takahashi A von Haeseler M Bader SS Kilic Y Ueta C Pifl S Narumiya JM Penninger 2009 Central control of fever and female body temperature by RANKL/RANK Nature 462 505 509 10.1038/nature08596 19940926 10.1038/nature08596 1:CAS:528:DC%2BD1MXhsVylsLzK
81. R Dantzer 2001 Cytokine-induced sickness behavior: mechanisms and implications Ann NY Acad Sci 933 222 234 12000023 10.1111/j.1749-6632.2001. tb05827.x 1:CAS:528:DC%2BD3MXjvVWqtrc%3D (Pubitemid 32386037)
82. CM Blatteis S Li Z Li C Feleder V Perlik 2005 Cytokines, PGE2 and endotoxic fever: a re-assessment Prostaglandins Other Lipid Mediat 76 1 18 10.1016/j.prostaglandins.2005.01.001 15967158 1:CAS:528:DC%2BD2MXks1arsLw%3D (Pubitemid 40720399)
83. F Ushikubi E Segi Y Sugimoto T Murata T Matsuoka T Kobayashi H Hizaki K Tuboi M Katsuyama A Ichikawa T Tanaka N Yoshida S Narumiya 1998 Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 Nature 395 281 284 10.1038/26233 9751056 10.1038/26233 1:CAS:528:DyaK1cXmtFejsL8%3D (Pubitemid 28447553)
84. C Handschin BM Spiegelman 2008 The role of exercise and PGC1alpha in inflammation and chronic disease Nature 454 463 469 10.1038/nature07206 18650917 10.1038/nature07206 1:CAS:528:DC%2BD1cXovV2mtbk%3D
85. A Mantovani P Allavena A Sica F Balkwill 2008 Cancer-related inflammation Nature 454 436 444 10.1038/nature07205 18650914 10.1038/nature07205 1:CAS:528:DC%2BD1cXovV2mtbg%3D